Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer

被引：3

作者：

Bracken-Clarke, Dara B. ^{[1
]}

Lucas, Mairi W. ^{[1
]}

Higgins, Michaela J. ^{[1
]}

机构：

[1] Mater Misericordiae Univ Hosp, Dept Med Oncol, Eccles St, Dublin 7, Ireland

来源：

BREAST CARE | 2017年 / 12卷 / 03期

关键词：

Adjuvant treatment; Aromatase inhibitors; Breast cancer; Endocrine therapy; Tamoxifen; FIRST-LINE THERAPY; POSTMENOPAUSAL WOMEN; DISTANT RECURRENCE; OVARIAN SUPPRESSION; UPDATED FINDINGS; TAMOXIFEN; ANASTROZOLE; LETROZOLE; TRIAL; EXEMESTANE;

D O I：

10.1159/000477956

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite meaningful, incremental improvements in detection, local treatment and adjuvant systemic treatments for breast cancer, there remains a significant risk of late relapse in hormone receptor (HR)-positive disease. 5 years of tamoxifen or an aromatase inhibitor for all patients with HR-positive early breast cancer is considered standard; however, there are now data to support an extended approach using up to 10 years of treatment. This review will provide some historical background on endocrine therapy and summarize the key clinical trials that demonstrate the small absolute benefit of extended adjuvant therapy. We provide suggested treatment algorithms for both premenopausal and postmenopausal patients and an overview of ongoing adjuvant trials. (C) 2017 S. Karger GmbH, Freiburg

引用

页码：138 / 144

页数：7

共 37 条

[1]

[Anonymous], CANC RES

[2]

[Anonymous], CANCER

[3]

[Anonymous], J NATL CANC I

[4]

[Anonymous], 2013, J CLIN ONCOL, V31, P5, DOI [DOI 10.1200/JCO.2013.31.18SUPPL.5, 10.1200/jco.2013.31.18_suppl.5]

[5] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].

Bonneterre, J ;

Thürlimann, B ;

Robertson, JFR ;

Krzakowski, M ;

Mauriac, L ;

Koralewski, P ;

Vergote, I ;

Webster, A ;

Steinberg, M ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757

[6]

Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO

[7]

2-Y

[8] Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy [J].

Buus, Richard ;

Sestak, Ivana ;

Kronenwett, Ralf ;

Denkert, Carsten ;

Dubsky, Peter ;

Krappmann, Kristin ;

Scheer, Marsel ;

Petry, Christoph ;

Cuzick, Jack ;

Dowsett, Mitch .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11)

[9] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[10] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J].

Davies, Christina ;

Pan, Hongchao ;

Godwin, Jon ;

Gray, Richard ;

Arriagada, Rodrigo ;

Raina, Vinod ;

Abraham, Mirta ;

Medeiros Alencar, Victor Hugo ;

Badran, Atef ;

Bonfill, Xavier ;

Bradbury, Joan ;

Clarke, Michael ;

Collins, Rory ;

Davis, Susan R. ;

Delmestri, Antonella ;

Forbes, John F. ;

Haddad, Peiman ;

Hou, Ming-Feng ;

Inbar, Moshe ;

Khaled, Hussein ;

Kielanowska, Joanna ;

Kwan, Wing-Hong ;

Mathew, Beela S. ;

Mittra, Indraneel ;

Mueller, Bettina ;

Nicolucci, Antonio ;

Peralta, Octavio ;

Pernas, Fany ;

Petruzelka, Lubos ;

Pienkowski, Tadeusz ;

Radhika, Ramachandran ;

Rajan, Balakrishnan ;

Rubach, Maryna T. ;

Tort, Sera ;

Urrutia, Gerard ;

Valentini, Miriam ;

Wang, Yaochen ;

Peto, Richard .

LANCET, 2013, 381 (9869) :805-816

← 1 2 3 4 →